Novofarma
Novofarma, officially known as Novofarma S.A., is a prominent player in the pharmaceutical industry, headquartered in Chile (CL). Founded in 1995, the company has established a strong presence across Latin America, focusing on the development, manufacturing, and distribution of high-quality pharmaceutical products. Specialising in prescription medications, Novofarma is recognised for its innovative approach to healthcare solutions, particularly in therapeutic areas such as cardiology, oncology, and infectious diseases. The company’s commitment to research and development has led to several key milestones, positioning it as a trusted name in the market. With a diverse portfolio of unique formulations and a dedication to improving patient outcomes, Novofarma continues to enhance its market position, contributing significantly to the healthcare landscape in the regions it serves.
DitchCarbon Score
How does Novofarma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Business Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Novofarma's score of 3 is lower than 85% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Novofarma's reported carbon emissions
Novofarma Service S.A., headquartered in Chile, has set ambitious climate commitments aimed at significantly reducing its greenhouse gas emissions. Although specific emissions data for the most recent year is not available, the company has established a target to reduce its Scope 1 and Scope 2 emissions by 42% by 2030, using 2022 as the base year. This target has been validated through a streamlined process designed for small and medium-sized enterprises (SMEs) and aligns with the science-based targets necessary to limit global warming to 1.5°C. In addition to its focus on Scope 1 and Scope 2 emissions, Novofarma is also committed to measuring and reducing its Scope 3 emissions, which encompass indirect emissions from its value chain. These initiatives reflect Novofarma's dedication to sustainability and its proactive approach to addressing climate change within the trading and commercial services sector.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Novofarma is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
